Chelsea Labs
Executive Summary
Leonard Wydotis has retired as president of the generic drug manufacturer. Chelsea's parent company, Rugby-Darby Group, said that a plan to move the Chelsea president from New York to Monroe, North Carolina, the location of Chelsea's manufacturing headquarters, was the reason behind Wydotis' decision to retire. A search is underway for a replacement. Chelsea has been under FDA scrutiny because of alleged untrue statements and discrepancies in manufacturing records for certain ANDAs. FDA is planning to withdraw ANDAs and downgrade the therapeutic rating for five drugs to therapeutically inequivalent and, reportedly, is reviewing over two dozen of Chelsea's ANDAs for batch record and formulation inconsistencies.
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.